ORIC Pharmaceuticals, Inc.ORICNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-5.81%
↓ 176% below average
Average (26q)
7.69%
Historical baseline
Range
High:37.16%
Low:-22.93%
Volatility
781.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -5.81% |
| Q2 2025 | 23.98% |
| Q1 2025 | -22.93% |
| Q4 2024 | 2.46% |
| Q3 2024 | 7.82% |
| Q2 2024 | 31.79% |
| Q1 2024 | -10.30% |
| Q4 2023 | 9.35% |
| Q3 2023 | 19.17% |
| Q2 2023 | -3.74% |
| Q1 2023 | 19.77% |
| Q4 2022 | 10.68% |
| Q3 2022 | 6.43% |
| Q2 2022 | -17.79% |
| Q1 2022 | 0.50% |
| Q4 2021 | 29.82% |
| Q3 2021 | -16.87% |
| Q2 2021 | 32.66% |
| Q1 2021 | -3.43% |
| Q4 2020 | 37.16% |
| Q3 2020 | 14.35% |
| Q2 2020 | 6.47% |
| Q1 2020 | 4.22% |
| Q4 2019 | 23.58% |
| Q3 2019 | 11.75% |
| Q2 2019 | -3.30% |
| Q1 2019 | 0.00% |